Head-to-head · WeighScore
TeleHealth Med vs Teleios Health
The verdict
TeleHealth Med takes it — 66.1/100 to 60.2/100.
TeleHealth Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleHealth Med (TeleHealth Med, Inc.) is a Georgia-based telehealth weight-loss platform offering compounded semaglutide and tirzepatide in both injectable and sublingual forms through US-licensed…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | TeleHealth Med | Teleios Health |
|---|---|---|
| WeighScore | 66.1/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #209 | #327 |
| Semaglutide | $147/mo (starting dose, compounded) | $99/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $139/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #209 · C
Strengths
- Corporate entity disclosed (TeleHealth Med, Inc.) — clearer accountability than undisclosed competitors
- Publishes the FDA compounded-medication disclaimer
- 503A pharmacy designation stated in the FAQ
- Honest disclosure that testimonials are compensated and results aren't independently verified
- Both injectable and sublingual forms offered
Where it loses points
- Specific 503A pharmacy partner not named
- LegitScript ID number not shown in text — only a verification link
- Full states-served list not disclosed
- Named medical director not disclosed
- Dose tiers beyond the $147/mo starting price not published
Graded #327 · C
Strengths
- Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
- Compounded tirzepatide from a competitive $139/mo floor
- Markets physician (MD/DO) prescribing rather than an NP-only model
- Clean meta-tag and SEO implementation
Where it loses points
- Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
- No named medical director, physician, or corporate entity disclosed
- Year founded unknown — a newer floor-price entrant warranting extra scrutiny
- No LegitScript, NABP, or SOC 2 trust signal found
- Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.